Forty one elderly patients admitted to hospital for acute illnesses were also found to have subclinical osteomalacia. Immediately before discharge, therefore, all were randomised to receive either vitamin D2 25 sLg daily, alfacalcidol 0-5 Ftg daily, or placebo. Treatment was given for at least three months, those allocated to placebo then being switched to an active drug.
Introduction
Vitamin D deficiency is a common problem in the elderly,1-4 although it may be difficult to recognise on purely clinical grounds5 (J R Kemm et al, paper submitted for publication). As the first sign may be fracture of a femoral neck6 one option is to screen at risk populations for abnormality in order to offer prophylactic treatment. If, however, patients without symptoms are to be treated in the expectation of future benefit then it is essential to show that this course of action is without risk.
A survey of the prevalence of vitamin D deficiency in an acutely ill hospital population4 identified several cases of subclinical osteomalacia. This provided an opportunity to assess the safety of treatment and to compare the therapeutic efficacy of vitamin D2 with that of alfacalcidol. This second preparation was chosen because renal impairment is common in this type of patient (J R Kemm et al, paper submitted for publication) and, unlike vitamin D, it does not require renal 1 x-hydroxylation for biochemical activity. The effect of treatment on the histological components of vitamin D deficiency is described elsewhere,7 and the present paper considers only the safety of this intervention.
Patients and methods
The screening programme (J R Kemm et al, paper submitted for publication) based on fasting measurements of serum calcium, phosphate, and alkaline phosphatase on the morning after admission to hospital identified 41 The maximum decrease in the amount of osteoid usually occurred within the first three months of treatment, by which time most values lay within the reference range for these measurements. 7 Hypercalcaemia was an uncommon problem with the doses of vitamin D2 and alfacalcidol used in the study. Figure 1 shows the serum calcium concentrations before and after the first three months BRITISH MEDICAL JOURNAL VOLUME 289 29 SEPTEMBER 1984 of treatment. Of the 56 treatment periods, only four were accompanied by a mild increase in the serum calcium value (to 2-6-2-7 mmol/l (10-4-10 8 mg/100 ml)). One patient, however, was hypercalcaemic before treatment and remained so throughout. In the remaining patients the mild hypercalcaemia found at three months was an isolated event, subsequent measurements giving values within the normal range. There was no tendency of the serum calcium concentration to rise with time. In 10 patients treated with alfacalcidol the mean serum calcium concentrations at zero, three, and six months were 2 31 (SD 0-17), 2-38 (0 19), and 2-25 (0 20) mmol/l respectively (9-24 (SD 0-68), 9-52 (0-76), and 9 00 (0 80) mg/100 ml). Comparable values for 16 patients treated with vitamin D, were 2-27 (SD 0-16), 2-28 (0 12), and 2 33 (0-13) mmol/l (9 08 (SD 0-64), 9 12 (0A48), and 9-32 (0-52) mg/100 ml).
In order to determine whether the presence of osteoid protects against vitamin D induced hypercalcaemia the concentration of serum calcium and the mean osteoid seam width were compared before and after three months' treatment (fig 2) . The findings showed no correlation between these variables, and-particularly importantminor amounts of osteoid were not associated with an increased risk of hypercalcaemia.
None of the episodes of hypercalcaemia were accompanied by evidence of a deterioration in renal function. Although four patients treated with alfacalcidol or vitamin D2 showed a rise in serum creatinine concentration (fig 3) , this invariably reflected progression of the underlying disease for which they had originally been admitted to hospital. -----=Line of identity.
Conversion: SI to traditional units-Creatinine: 1 tLmol/l1 0.01 mg/100 ml.
Discussion
If treatment of subclinical osteomalacia in the elderly is to gain general acceptance then it is essential to know that it is both safe and effective. We have already shown that the second of these objectives may be achieved by a relatively short three month course of replacement therapy.7 The safety of this type of treatment, however, particularly with respect to the risk of developing hypercalcaemia or renal impairment, depends on several factors.
Vitamin D2 in the dose used here (25 ,tg daily) has inherent safety because both the hepatic and renal hydroxylations which are needed to achieve full biological potency are carefully regulated in vivo. 9 Unfortunately, renal impairment was a common feature of the elderly hospital population studied (J R Kemm et al, paper submitted for publication), and this type of patient tends to respond poorly to vitamin D2. The requirement for renal hydroxylation may be avoided by the use of alfacalcidol,9 but since the regulatory mechanisms which 'A protect against toxicity are bypassed doubt has been expressed about its safety in the elderly.'0 Our study, however, shows that in the dose needed to heal subclinical osteomalacia (0-5 .g daily)7 alfacalcidol proved free from the risk of hypercalcaemia. Although there were four episodes of hypercalcaemia, the circumstances under which this occurred suggested that it was not due to vitamin D intoxication. Moreover, none of the episodes was accompanied by a deterioration in renal function. In this type of study it is very difficult to separate the effects of treatment on renal function from those of unrelated systemic disease. In the few instances of an increase in serum creatinine concentration this appeared to be due to progression of the underlying illness which had precipitated the patients' original hospital admission rather than to a side effect of treatment."
Experience with renal osteodystrophy has shown that although hypercalcaemia may appear in the early stages of treatment, it may also develop for the first time when the osteomalacia has almost healed.'2 13 This is a reflection of skeletal uptake of calcium as osteoid remineralises which offsets any tendency of calcium absorption, stimulated by treatment, to cause hypercalcaemia. This buffering capacity, however, is progressively lost as the bone disease heals. Hence there was some anxiety that the small excess of osteoid in the elderly patients in this series would be insufficient to protect them against hypercalcaemia. Fortunately, it is clear that the posttreatment serum calcium concentration is not critically dependent on the presence or extent of trabecular osteoid. The safety of the present regimen is probably a function of dose, since patients with hypoparathyroidismt4 or osteoporosis15 (who also do not have an excess of osteoid) may become hypercalcaemic when treated with larger doses of alfacalcidol or calcitriol.
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(Accepted 27_June 1984) Effect of an oral serotonin antagonist, ketanserin, on plasma ACTH concentrations in Nelson's syndrome R W G PRESCOTT, W A RATCLIFFE, P KENDALL TAYLOR Abstract A study was performed to see whether ketanserin, a serotonin antagonist, would reduce the raised concentrations of adrenocorticotrophic hormone (ACTH) in patients with Nelson's syndrome. Six patients who had undergone bilateral adrenalectomy for Cushing's disease and who had Nelson's syndrome were given ketanserin 40 mg twice daily and placebo, for at least two months each, in a double blind crossover study. Ketanserin had no effect on ACTH concentrations.
In healthy people serotonin seems to have a stimulatory role in the regulation of ACTH secretion, and the effect of ketanserin in reducing the ACTH response to hypoglycaemia suggested that it might prove useful in Nelson's syndrome. These results show that it is not indicated in these patients.
Introduction
Nelson's syndrome, characterised by increased skin pigmentation and high circulating adrenocorticotrophic hormone (ACTH) concentrations, results from the development of an ACTH secreting pituitary adenoma after bilateral adrenalectomy for Cushing's disease. Once it has developed the adenoma can be locally invasive and difficult to control by either irradiation or hypophysectomy. Hence there is a need for effective drug treatment, and drugs which may alter the neurotransmitter control of ACTH have been tried in this condition.' 2 Serotonin influences the release of corticotrophin releasing factor, and the relatively weak and non-specific antiserotonin agent cyproheptadine is sometimes useful in Cushing's disease or Nelson's syndrome.' Ketanserin is a new and specific serotonin antagonist, and the present double blind study was therefore designed to evaluate its effect on the ACTH concentrations of patients with Nelson's syndrome.
Patients and methods
Five women and one man aged 36-65 years were studied. All had undergone bilateral adrenalectomy for Cushing's disease five to 23 years previously. The pituitary fossa was enlarged in two patients. Three patients had received external irradiation to the pituitary six to 17 years previously. Characteristic increased pigmentation was present in five patients, and in the sixth pigmentation had resolved after external irradiation, although plasma ACTH concentrations remained raised. All patients were receiving hydrocortisone replace-
